Research Topics
| J R KorzenikSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Case closed? Diverticulitis: epidemiology and fiberJoshua R Korzenik
MGH Crohn s and Colitis Center, Gastrointestinal Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA
J Clin Gastroenterol 40:S112-6. 2006..This understanding, if demonstrated, would have important implications for the primary and secondary prevention of diverticulitis...- Past and current theories of etiology of IBD: toothpaste, worms, and refrigeratorsJoshua R Korzenik
IBD Center, Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
J Clin Gastroenterol 39:S59-65. 2005..A variety of changes in the gut flora, ranging from a basic dysbiosis to the absence of helminths, have been proposed as the root cause of inflammatory bowel disease... - Diverticulitis: new frontiers for an old country: risk factors and pathogenesisJoshua R Korzenik
Department of Internal Medicine, Massachusetts General Hospital, MGH Crohn s and Colitis Center, Boston, MA 02114, USA
J Clin Gastroenterol 42:1128-9. 2008..Despite these evidences, the risk factors and pathophysiology progression from asymptomatic diverticular disease to diverticulitis have been inadequately studied. This subject is reviewed in more detail in this manuscript... - Sargramostim for active Crohn's diseaseJoshua R Korzenik
Inflammatory Bowel Disease Center, Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, USA
N Engl J Med 352:2193-201. 2005..Preliminary studies suggest sargramostim may have activity in Crohn's disease. To evaluate this novel therapeutic approach, we conducted a randomized, placebo-controlled trial... - An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's diseaseJ R Korzenik
Department of Internal Medicine, Inflammatory Bowel Disease Center, Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Aliment Pharmacol Ther 21:391-400. 2005..Anecdotal cases using haemopoietic colony-stimulating factors report improvement in intestinal disease associated with these syndromes... - Is Crohn's disease due to defective immunity?J R Korzenik
Department of Internal Medicine, Massachusetts General Hospital, MGH Crohn s and Colitis Center, 165 Cambridge Street, 9th Floor, Boston, MA 02114, USA
Gut 56:2-5. 2007..Recent advances in genetics, functional studies on innate immunity and therapeutic trials on patients with Crohn's disease have lent support to this evolving hypothesis... - Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximabJoshua R Korzenik
Gastrointestinal Unit, Department of Internal Medicine, Massachusetts General Hospital, 55 Fruit Street Boston, MA 02114 2622, USA
Gastroenterol Clin North Am 33:285-301, ix. 2004..This article focuses on those agents, other than infliximab, which target TNF-alpha to treat inflammatory bowel disease as their central mechanism of action... - Infliximab maintenance therapy for fistulizing Crohn's diseaseBruce E Sands
Gastrointestinal Unit, Massachusetts General Hospital, and Harvard Medical School, Boston 02114, USA
N Engl J Med 350:876-85. 2004.... - Risks and benefits of infliximab for the treatment of Crohn's diseaseCorey A Siegel
Section of Gastroenterology and Hepatology, Inflammatory Bowel Disease Center, Dartmouth-Hitchcock Medical Center, Dartmouth Medical School, Lebanon, New Hampshire, USA
Clin Gastroenterol Hepatol 4:1017-24; quiz 976. 2006..These data should help guide decision making and the informed consent process when considering the use of infliximab for the treatment of Crohn's disease... - Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease QuestionnaireManuel Y Lam
MGH Crohn s and Colitis Center and Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Inflamm Bowel Dis 15:599-607. 2009..We assessed the validity of an interactive voice response system (IVRS) as a new mode of administering the SIBDQ... - Validation of the functional assessment of chronic illness therapy-fatigue (FACIT-F) in patients with inflammatory bowel diseaseA Tinsley
Dr Henry D Janowitz Division of Gastroenterology, Mount Sinai School of Medicine, NY 10029, USA
Aliment Pharmacol Ther 34:1328-36. 2011..76, 95% CI -0.89 to -0.50), CRP (-0.72, 95% CI -0.88 to -0.43) and HCT (0.53, 95% CI 0.22-0.74). CONCLUSION The FACIT-F scale is a reliable and valid instrument for measuring fatigue in IBD... - LRRK2 is involved in the IFN-gamma response and host response to pathogensAgnès Gardet
Center for the Study of the Inflammatory Bowel Disease, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
J Immunol 185:5577-85. 2010..These observations indicate that LRRK2 is an IFN-γ target gene, and it might be involved in signaling pathways relevant to Crohn's disease pathogenesis... - Crohn's disease: innate immunodeficiency?Jesus K Yamamoto-Furusho
Gastrointestinal Unit, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114, USA
World J Gastroenterol 12:6751-5. 2006.... - Evolving knowledge and therapy of inflammatory bowel diseaseJoshua R Korzenik
Gastrointestinal Unit, Department of Medicine, Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114, USA
Nat Rev Drug Discov 5:197-209. 2006..With increasing evidence for a crucial role for luminal flora in maintaining the health of the bowel, strategies to manipulate intestinal bacteria using probiotics and prebiotics are being actively investigated as well... - Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factorBrian K Dieckgraefe
Division of Gastroenterology, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Box 8124, St Louis, MO 63110, USA
Lancet 360:1478-80. 2002..Retreatment was effective, and treatment was associated with increased quality-of-life measures. GM-CSF may offer an alternative to traditional immunosuppression in treatment of Crohn's disease... - Inflammatory bowel disease and environmental influencesAruna Krishnan
Department of Internal Medicine, Washington University School of Medicine, 4950 Children's Place, Box 8121, St. Louis, MO 63110, USA
Gastroenterol Clin North Am 31:21-39. 2002..The conflicting evidence in many of these studies may be clarified as specific genes are identified and the interplay between these environmental factors and genetic subtypes is investigated... - Growth factors as treatment options for intestinal inflammationBrian K Dieckgraefe
Division of Gastroenterology, Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
Ann N Y Acad Sci 1072:300-6. 2006..These data focus on the reparative components of mucosal homeostasis... - Probiotics for recurrent Clostridium difficile diseaseSteven J Lawrence
J Med Microbiol 54:905-6. 2005 - Association of glycogen storage disease 1b and Crohn disease: results of a North American surveyBrian K Dieckgraefe
Washington University School of Medicine 660 S Euclid Ave, Campus Box 8124, St Louis, MO 63110, USA
Eur J Pediatr 161:S88-92. 2002..Additional investigations into the intestinal disease in glycogen storage disease type 1b may be directly relevant to the etiology and treatment of idiopathic Crohn disease...